

### **Disclaimer**

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

**straumann**group

\_\_\_\_\_\_






# Back to business... Dentists open Europe APAC NAM Emerging mkts LATAM Straumann open Europe APAC NAM Emerging mkts LATAM LATAM Emerging mkts LATAM LATAM

5

### ...prepared for uncertainty Single-hit: Best case Straumann adapts Single-hit scenario - - · OECD forecast ■ Global economic activity falls - Worst case 6% in 2020 Safety for staff and - - · OECD forecast Double-hit: customers ■ OECD unemployment >9% Living standards fall Business continuity 110 ■ 5 years of income growth lost assured across the economy by 2021 100 Financial impact 90 mitigation Double-hit scenario • Liquidity secured 80 ■ New outbreak; return to lockdowns this year • Organization right sized 70 ■ World economic output falls 8%; back 3% in 2021 • Ready to bounce back 60 ■ OECD unemployment 10% with little recovery by 2021 2019-Q4 2020-Q2 2020-Q4 2021-Q4 **straumann**group


6


**straumann**group





Q2: APAC picks up, EMEA & NAM through the worst; **LATAM** still fighting hard Organic revenue growth **SEMEA** NAM Q1 2020 Q1 2020 7.7% 0.1% Q2 2020 - 41.6% Q2 2020 - 38.0% APAC - 22.1% Q1 2020 Q2 2020 - 11.7% **LATAM** Q1 2020 7.2% Group Q2 2020 60.3% Q1 2020 - 1.4% Q2 2020 - 35.9% straumanngroup 8

# Business and regional review Peter Hackel, CFO









Summary of major effects in H1 2020

Revenue declines due to COVID-19 pandemic and economic deceleration
 Short-time work subsidies CHF 12m (reported under 'other income')

- Reduction of global workforce by 9%; restructuring costs of CHF 13m\*
- Impairments of CHF 150m\*
- Straight bond issue in April for CHF 280m, replacing matured bond of CHF 200m; second straight bond issue in June for CHF 200m, paid in July
- Committed credit lines for CHF 400m secured

**straumann**group

# Core financials at a glance

In CHF million, rounded	H1 2020	% of revenue	Margin change	Change in %	Comments
Revenue	605.1	100.0%		(22.4%)	
COGS	(175.3)	29.0%		(1.3%)	
GROSS PROFIT	429.8	71.0%	(620bps)	(28.7%)	FX headwind -90bps
Operating expenses	(329.6)	54.4%		(15.1%)	
EBIT	100.2	16.6%	(1090bps)	(53.2%)	FX headwind -150bps
Financial result	(12.1)	2.0%		13.1%	
Associates	(1.9)	0.3%		37.4%	
Income tax	(12.6)	2.1%		(61.2%)	
NET PROFIT	73.6	12.2%	(950bps)	(56.6%)	
Basic EPS	4.49			(57.8%)	

**straumann**group


15


## Reported financials at a glance


In CHF million, rounded	H1 2020	% of revenue	Margin change	Change in %	Comments
Revenue	605.1	100.0%		(22.4%)	
COGS	(183.8)	30.4%		(0.6%)	
GROSS PROFIT	421.3	69.6%	(670bps)	(29.2%)	
Operating expenses	(495.1)	81.8%		19.1%	
EBIT	(73.8)	(12.2%)	(3520bps)	(141.2%)	Impairments -2510bps Restructuring -240bps FX headwind -170bps
Financial result	(22.2)	3.7%		107.5%	Thereof loan impairment 10.1m
Associates	(1.9)	0.3%		(141.8%)	
Income tax	4.3	0.7%		(116.0%)	Positive effect due to impairments
NET PROFIT	(93.7)	(15.5%)	(3430bps)	(164.0%)	Financial impairment -170bps
Basic EPS	(5.89)			(164.0%)	


**straumann**group

rview: core re	sults	reco	oncil	iation	CORE	CORE	
(in CHF 1 000)	IFRS	amortization	Impairments <sup>1</sup>	Restructuring <sup>2</sup>	HY1 2020	HY1 2019	
Revenue	605 088				605 088	780 034	
Cost of goods sold	(183 791)	70	7 649	805	(175 267)	(177 554)	
Gross profit	421 298	70	7 649	805	429 822	602 480	
Other income	13 927	10100			13 927	2 134	
Distribution expense	(163 671)	4 419	12 314	6 321	(140 617)	(159 467)	
Administrative expense	(345 356)	2 691	132 112	7 624	(202 929)	(231 003)	
Operating profit	(73 802)	7 180	152 075	14 750	100 203	214 144	
Finance income	41 678				41 678	34 159	
Finance expense	(63 921)		10 118		(53 803)	(44 877)	
Gain on consolidation of former associates	0				- Comments		
Share of result of associates	(1 911)				(1911)	(1 392)	
Profit before income tax	(97 956)	7 180	162 193	14 750	86 167	202 034	
Income tax expense	4 256	(2 018)	(12 613)	(2 213)	(12 588)	(32 464)	
NET PROFIT	(93 700)	5 162	149 580	12 538	73 579	169 570	
Attributable to:							
Shareholders of the parent company	(93 462)	5 015	147 139	12 538	71 229	168 614	
Non-controlling interests	( 239)	147	2 441		2 350	955	
Basic earnings per share (in CHF)	-5.89				4.49	10.64	
Diluted earnings per share (in CHF)	-5.88				4.48	10.60	
Operating profit	(73 802)	7 180	152 075	14 750	100 203	214 144	
Depreciation & amortization	197 736	(7 180)	(149 975)		40 581	(32 340)	
EBITDA	123 934	11 1007	2 100	14 750	140 784	246 483	









Adapting to the new reality & customer focus

Guillaume Daniellot, CEO

22

**straumann**group

## Massive online outreach to customers during lock-down







**straumann**group

23

# Strategy in action Guillaume Daniellot, CEO





FDA cleared

Strategic door-opener to certain large clinics

to zygomatic implant users

Opportunity to supply other implants (e.g. BLX) & products

straumanngroup

## Ortho business update

### ClearCorrect 'ONE' launched

• 1 price, 1-year treatment, 1 revision, 1 free retainer set

### New high-performance material

- Triple-layer; exerts constant forces even after 7 days, improving performance by 2-3 days
- High comfort and stain resistance
- Launch in Q3, earlier than expected

### Aligner production in Markkleeberg operational

- Capacity: 10K aligners per day
- Highly automated
- Can be expanded & replicated in other locations



Elastomeric middle layer


Dual shells

Ortho solution push

27


# DrSmile – a leading provider of doctor-led clear-aligner treatment solutions in Europe

- solutions in Europe
- Expertise in consumer marketing, combined with clinician-led aligner treatment
- Focused on simple to moderate cases with strict selection
- Network of clinics & partners open to all dentists
- Founded 2017, based in Germany, expanding in Austria & Spain, revenue doubled annually
- Agreement in July for Straumann to acquire majority stake
- Complements Straumann's existing clear-aligner business



**straumann**group

28





# Artificial intelligence to enhance diagnosis and facilitate virtual treatment workflows



- 49% non-controlling stake in Promaton B.V.
- Netherlands-based company specializing in artificial intelligence in dentistry automation
- Put/call-option mechanism for a stepped increase to full ownership in 2023



**straumann**group

31

# Outlook

## **Outlook – uncertainty continues**

### Market

- · Signs of recovery as most countries/regions have re-opened
- Practices adapt to new safety standards, but efficiency reduced
- Difficult to determine whether present improvement will continue at same pace if further waves of COVID-19 occur
- Potential of weak macro-economic environment a concern

# Our revenue and profitability

- · Underlying business fundamentals are intact
- Group confident to emerge as an even stronger partner of choice when economy and consumer confidence return to normal
- Current uncertainties prevent Group from guiding for full-year revenue & earnings.



**straumann**group

33





# **Calendar of upcoming reporting dates**

2	2020	Event	Location
2	28 October	Q3 results publication	Webcast

**straumann**group

